financetom
Business
financetom
/
Business
/
Takeda Pharmaceutical's Adzynma Under US FDA Probe Following Death of Pediatric Patient
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Takeda Pharmaceutical's Adzynma Under US FDA Probe Following Death of Pediatric Patient
Nov 21, 2025 7:15 AM

09:50 AM EST, 11/21/2025 (MT Newswires) -- Takeda Pharmaceutical's ( TAK ) Adzynma is being investigated by the US Food and Drug Administration following the death of a pediatric patient related to the drug, which is intended to treat congenital thrombotic thrombocytopenic purpura, the regulator said Friday.

"Prior to treatment with Adzynma, this patient had severe allergic reactions to fresh frozen plasma," the FDA said. "The patient presented with neurologic symptoms which progressed, and the presence of neutralizing antibodies to ADAMTS13 was identified approximately 10 months after starting prophylactic treatment with Adzynma."

The FDA said the probe will investigate the risk of patients developing neutralizing antibodies with "serious, including life-threatening or fatal, outcomes following treatment with Adzynma." It also said it will determine if additional regulatory action is needed.

The FDA also said current assays cannot distinguish neutralizing antibodies to recombinant ADAMTS13 from neutralizing antibodies to endogenous ADAMTS13.

In November 2023, Takeda said the FDA approved Adzynma for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura.

Price: 14.13, Change: +0.06, Percent Change: +0.39

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cintas Lifts Annual Guidance After Posting Stronger-Than-Expected Fiscal Third-Quarter Results
Cintas Lifts Annual Guidance After Posting Stronger-Than-Expected Fiscal Third-Quarter Results
Mar 27, 2024
11:02 AM EDT, 03/27/2024 (MT Newswires) -- Shares of Cintas ( CTAS ) climbed on Wednesday after the uniform supplier reported stronger-than-expected top- and bottom-line growth for the fiscal third quarter and sweetened its full-year outlook. Revenue climbed to $2.41 billion for the three months ended Feb. 29 from $2.19 billion a year ago and surpassed the $2.39 billion average...
Satellos Bioscience Announces FY 2023 Results
Satellos Bioscience Announces FY 2023 Results
Mar 27, 2024
11:04 AM EDT, 03/27/2024 (MT Newswires) -- Satellos Bioscience Inc. ( MSCLF ) , a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, on Wednesday reported its FY 2023 results. The company recorded a net loss of $15.9 million, compared with a net loss $11.3 million, for the year ended...
Verb Technology's Market.live Teams Up With TikTok; Shares Rise
Verb Technology's Market.live Teams Up With TikTok; Shares Rise
Mar 27, 2024
11:08 AM EDT, 03/27/2024 (MT Newswires) -- Verb Technology ( VERB ) said Wednesday it has entered into a partnership with TikTok Shop, making its Market.live a service provider for TikTok Shop and a designated TikTok Shop Partner. Under the partnership, TikTok Shop will direct leads to Market.live for onboarding, training, studio space rental , content creation and production services,...
Russian company starts Citroen production at former Stellantis factory
Russian company starts Citroen production at former Stellantis factory
Mar 27, 2024
MOSCOW (Reuters) - Russian company Automotive Technologies on Wednesday said it had started assembling Citroen C5 Aircross models in batches at a plant south of Moscow formerly owned by Stellantis, with the cars set to be sold in dealerships from May. Reuters exclusively reported in February, citing customs data and two people familiar with the matter, that Automotive Technologies had...
Copyright 2023-2026 - www.financetom.com All Rights Reserved